(as of 9/27/2022)
Sleep is a highly sensitive digital biomarker of the brain. We believe that measuring sleep with high precision will lead to a better understanding of the pathology of brain and mental illnesses. For example, psychiatric disorders such as depression, bipolar disorder, and schizophrenia; developmental disorders such as attention-deficit/hyperactivity disorder and autism spectrum disorder; and central neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease occur together in many patients with sleep disorders. Our strength is our service using the world's most accurate sleep measurement technology. ACCEL, the world's most accurate sleep measurement technology, can detect mid-onset arousal with extremely high accuracy. Fitbit and Apple watch can detect mid-awakening only 50% of the time, but our ACCEL can detect mid-awakening more than 80% of the time.
Acorai is developing a device for heart failure management through non-invasive intracardiac pressure monitoring (ICPM), to help reduce hospitalizations and readmissions. Our product, The Acorai Heart Monitor, can monitor intracardiac pressures non-invasively through a machine learning analysis of pressure dynamics in acoustics, vibratory and waveform data. Our technology shows compelling precision, has a low-risk clinical and regulatory pathway, a low dependence on reimbursement and a fast track to commercialization.
Adiposs is a Swiss clinical stage company developing a disruptive medical imaging product called ImageBAT™, the first product that can detect a special type of body fat called brown fat. ImageBAT™enables cancer patient stratification by predicting the response to cancer immunotherapy and survival of cancer patients. It is an add-on product to the fast, non-invasive oncology follow-up CT scan available in every hospital worldwide.
AiM Medical Robotics is a neurosurgical robotics company that is working to bring high levels of precision, automation, and efficiency to the surgical suite by introducing portable MRI-functional robotics into the complex surgical environment of neurosurgery. We are developing a portable neurosurgical robot for use in the MRI scanner. Our mission is to improve outcomes for patients undergoing neurosurgery for functional brain disorders (Parkinson’s, Epilepsy, etc.) and Glioblastoma while providing cost savings to hospitals by eliminating error and reducing procedure time by up to 50%.
Ark Surgical is a woman`s health medical device company focused on uterine cancer prevention entering the commercialization phase.
Based in Galway, Ireland and Boston, MA, Atlantic Therapeutics develops and markets INNOVO®, the first non-invasive, wearable, clinically-proven, home-based therapy to treat Stress Urinary Incontinence, a condition that affects 1 in 3 women. The company's mission is to improve the quality of life of millions of people each year, by enabling them to restore and strengthen their pelvic health, thus regaining the confidence and control to lead active lives. Atlantic Therapeutics has attracted both international VC investment and enterprise grant funding and is experiencing high growth, establishing INNOVO® as the leading Femtech solution to treat SUI. For more information, please visit www.myinnovo.com.
bioProtonics’ µTexture in vivo, MR-based diagnostic provides the resolving power needed to measure the ultra fine tissue changes that are the earliest harbingers of disease, thus enabling most effective application of therapeutics.
CorVista Health is applying machine learning to develop a novel cardiac diagnostic platform, CorVista® System, with the aim of transforming cardiovascular care and the patient experience. The CorVista System is a non-invasive, point-of-care solution that allows physicians to evaluate heart function without radiation, contrast agents, injections, fasting or exercise. For more information, visit www.corvista.com. The CorVista System is an investigational device limited by federal law to investigational use. The CorVista System is not available for commercial distribution.
Cytokind is the global leader in using UVB light to treat immune disorders and improve survival and the quality of life for patients. The company seeks to provide a value based care model that includes treatment therapies and support to improve longevity and the quality of life across a broad range of disorders). By doing so, Cytokind will disrupt the care model for a broad range of disorders using UVB light in concert with digital therapeutics to create a new value and disease care paradigm to create more patient autonomy and less strain on the hospital care system. The company anticipates that their innovative research will lead to the development of new nutraceuticals and drugs to improve chronic and acute care. We need to re-imagine our relationship with the sun. Cytokind invites you to follow the light. For more information about Cytokind and our scientific discovery, please visit: www.cytokind.net
CytoVeris is a medical device manufacturer that develops optical-based technologies incorporating artificial intelligence to enable surgical oncologists to identify and remove tumor tissue during cancer resection surgery. Our Cancer Imaging platform, based on a proprietary Multi2-Spectral Auto-Fluorescence Imaging (MS-AFI) system, will assist cancer surgeons to discern between cancer tissue and healthy tissue in real-time during surgery and as a result will increase the probability of successful cancer surgery and outcomes in open, minimally invasive surgery (MIS) and robotically assisted (RA) procedures.
We are on a mission to give people the knowledge, guidance and inspiration to take control of their oral health – anytime and anywhere. DentiScope’s solution is the world’s first smartphone-mounted scope and AI-based Computer Vision oral health diagnostic system. Our easy-to-use App, our low-cost scope and our very affordable AI-based assessments will democratize oral care in terms of access, affordability and positive outcomes globally.
Enova’s Vision is to design, develop, manufacture and sell the most innovative and highest performing medical illumination and magnification products in the world, helping to improve surgical performance and medical and dental outcomes, by providing health care professionals with complete visualization solutions. Our Mission: We help doctors see better so they can perform better. We address the problems faced by the medical profession in dealing with compromised performance due to poor ergonomics and limited capabilities of their existing visualization tools. Our portfolio of illumination and magnification products serves the medical, dental, and veterinarian markets, domestically and internationally: specifically, our LED surgical headlights, optical loupes, micro-cameras, 3D microscopes, and soon our break-through A/R (augmented reality) visualization products - ScopEYE® Smart Glasses, ScopEYE U® (for ultrasound) and MetaSCOPE® e-loupe.
Entac Medical is a commercial stage digital health company developing IoT wearable devices using acoustic signals to predict patient adverse events in large markets with unmet medical need. Revenue generation is expected to begin 4Q22 with a significant ramp in 2023 with PrevisEA, predicting gastrointestinal impairment (GII) in surgery patients. The company is quickly advancing its rapid development IoT predictive wearables platform, PrevisAI, with a 2nd-generation device for GII (510(k) 2023) and development of devices in heart and lung conditions (Data 4Q22/1Q23). Entac is seeking $3M in convertible debt financing to expand PrevisEA commercialization, complete development of PrevisAI GII, and significant R&D milestones in heart and lung conditions.
Fusion Genomic’s mission is to provide actionable genomic data on infections to hospitals & Governments. Our innovative targeted metagenomic platform ONETest™ solves the adoption and data challenges for genomic tests by making then lower cost (20-25% of metagenomic tests) and easier to use (full automation and complete analysis platform). We continue to innovate, and our vision is to arm clinicians and government with effective data on infectious diseases by making genomic testing as cost-effective, rapid, and easy to use as current PCR tests.
Genome Insight is a cancer whole genome platform company with the goal to accelerate use of whole genome sequencing (WGS) for accurate diagnosis and personalized treatment for cancer and rare diseases. Our proprietary GINS platform is an automated WGS pipeline and computer system that can rapidly generate meaningful interpretation insights for clinicians and patients, making it possible to use WGS in real-life clinical settings. We are also active in research using the power of WGS to advance novel therapeutic strategies in cancer and rare diseases. Our company HQ is in San Diego (US) with R&D offices in Seoul and Daejeon (Korea). To learn more, visit www.genomeinsight.net
Harmonic Bionics is a commercial-stage robotics and digital health company disrupting the $12B+ physical medicine and rehabilitation markets through the digitization and automation of shoulder care. Led by a highly talented and successful leadership team with vast medical device experience, the Austin-TX based company has designed the first bilateral upper body robotic rehabilitation and assessment system with a biomechanically matched shoulder design. The unprecedented data sets produced by the system’s high-speed and high-fidelity sensors have the potential to transform the industry by helping to create standardized and automated therapy protocols to drive higher quality interventions, increasingly predictable outcomes, and significant cost-savings to facilities and payers.
iCardio.ai is a deep learning startup developing an AI Cardiologist for interpretation of echocardiograms (Ultrasound of the heart). Founded in Los Angeles by an interdisciplinary team of computer scientists and AI enthusiasts, iCardio.ai leverages perhaps the largest private dataset of echocardiograms in the United States to train its core product, the iCardio.ai Brain. The iCardio.ai Brain is a comprehensive AI system comprised of over 40 neural networks that can intake an ultrasound study and produce a full echo report in a manner that mimics the mind of a cardiologist. iCardio.ai is now working aggressively to commercialize this device and to that end, iCardio.ai has closed a 5 year collaboration with General Electric. With GE Healthcare, the firm is working to implement its brain across its North American install base of over 30,000 machines. iCardio.ai is similarly engaged with Clarius and other vendors around the world.
illumiSonics develops, patents and commercializes PARS® advanced optical imaging systems for a wide range of pre-clinical and clinical applications. Founded in 2014, illumiSonics is a privately held medical device company with offices and R&D facilities Waterloo, ON, Canada. The company's executive team of medical device leaders holds an excellent track record of successfully building companies and improving outcomes for clinicians and patients. The technical R&D teams are the pioneers in PARS technology. illumiSonics works with market leading partners to develop systems for specific applications.
Inmedix brings an essential new diagnostic, a new cloud platform and a new strategy to transform medicine, beginning with autoimmune disease . Next-generation Inmedix heart rate variability (HRV), the Inmedix Cloud diagnostics platform and its concept of Immuno-autonomics are the essence of applied transitional medicine to understand why patients respond differently to the same treatment.
Implandata is a transformational ophthalmic digital health/device company based in German and the US. We will improve the life of millions glaucoma patients by introducing remote disease management. Our CE marked EYEMATE system is ready for commercial launch in Europe and Breakthrough Device Designation ensures an expedited FDA market authorization process. CMS reimbursement for remote patient monitoring is in place. We are currently raising our last funding round prior an exit.
JOGO is an FDA cleared wearable and AI solution helping Providers monitor and treat chronic pain, musculoskeletal and neuromuscular conditions via telehealth. JOGO also develops digital therapeutics solutions for chronic pain and neuromuscular conditions. In a recent study conducted at Brigham and Women's Hospital/Harvard Medical School, JOGO demonstrated better efficacy than opioids in treating non-specific lower back pain.
Koliber Biosciences in an early-stage biotechnology company with a unique biologically inspired Artificial Intelligence platform for peptide drug discovery. The company is based in San Diego, CA with a world-class management team of 2 founders and 6 advisors with deep expertise in peptide drug discovery, peptide chemistry, immunology, machine learning and software development. Koliber has raised $1M in non-dilutive funding through SBIR grants and start-up competitions and is generating revenue from collaborative projects including with a top 20 pharma partner. Koliber is a women-owned company.
medical magnesium develops metallic bioabsorbable implants for orthopaedic and trauma surgical therapy, based on its mm.X implant technology. The mm.X implants are mechanically stable and will be physiologically absorbed by the body after the fracture has healed. Our goal is to provide users and patients customized and highly functional solutions made of magnesium. We aim to shape a next generation of implants to provide more therapy options with just a single surgery. As a start-up from RWTH Aachen University, we bring results from interdisciplinary research in engineering and medicine into the surgical theathres. After extensive testing, we developed the product technology mm.X and the first products were transferred into the clinic. We are committed to transparently publish all data with high clinical evidence.
Nisonic is a Norwegian ultrasound imaging and software company that is developing technology for non-invasive detection and measurement of increased intracranial pressure (ICP). The methods are based on measurements of physiological responses of the optic nerve complex caused by elevated intracranial pressure and is made possible by using ultrasound imaging and MACHINE LEARNING. Our mission is to offer technology that simplifies early detection of increased intracranial pressure and thereby contributing to saved lives and improved clinical outcomes. The company’s first product is the Nisonic P-100 ultrasound scanner (CE-marked) offering high quality transorbital imaging and automated image processing to obtain non-invasive markers of increased ICP.
Noninvasix is expected to be the first company to non-invasively monitor central venous oxygenation, a key indicator of the progression of sepsis to septic shock, enabling clinicians to diagnose and monitor the response to treatment of tissue hypoxia in real-time. Its patented optoacoustic platform technology is the first solution to non-invasively and continuously measure central venous oxygen saturation. Incorporating Noninvasix into the ICU workflow is expected to allow clinicians to more quickly and accurately diagnose their critically ill patients and tailor treatments to improve outcomes. Future developments, enhancements, and evidence will expand the use and clinical impact of the technology into other indications and settings.
Founded in Australia, Nutromics is developing a breakthrough platform technology that combines DNA sensors with microneedles. Our powerful technology can track multiple, clinically relevant targets continuously and in real-time, giving clinicians access to critical, personalized insights needed to save lives.
OBSTETRX, Inc. will substantially reduce maternal injury and death from postpartum hemorrhage (PPH) by commercializing a novel medical device capable of delivering life-saving uterine tamponade. XSTAT PPH is a variant of the award-winning XSTAT® hemorrhage control device for treating life-threatening trauma wounds, and is uniquely suited to fill current capability gaps in the treatment of PPH. The XSTAT PPH uses a simple obstetrical applicator to insert a porous pouch filled with compressed minisponges directly into a bleeding uterus. Once inside the uterus, the XSTAT PPH minisponges absorb blood and expand 10-15x their pre-compressed dimension within seconds.
PhotoPharmics specialize in treating neurodegenerative disorders through the eyes. We have 30+ years of research and experience in this field, developing specialized light solutions to regulate circadian rhythms for SAD, sleep disorders, anxiety, and depression (acquired by Philips-Respironics in 2007). These solutions are now used by millions. Neurodegenerative diseases show retinal deterioration, which may contribute to disease symptoms. These diseases, such as Parkinson’s disease, are also accompanied by circadian system dysregulation. Animal research and human pilot trials show that specialized wavelengths of light delivered in the right intensities and at the right time of day could reduce Parkinson’s symptoms. As a result of our work in this area, PhotoPharmics developed the use of specific wavelengths of light in Parkinson’s and conducted a pivotal human clinical trial to demonstrate its safety and efficacy.
Piccolo Medical Inc, a spin out of the Theranova Medical Device Incubator, has developed the SmartPICC® System for navigation and tip confirmation of peripherally inserted central catheters (PICC). The SmartPICC® System utilizes Piccolo’s patented Ionic Dilution technology to give the nurse a real time visualization of the blood flow condition at the tip of the catheter. The SmartPICC® System received 510(k) clearance in 2021 as an alternative to chest x-ray for confirming PICC location.
Our Vision is to create a world of bionic vision for those who have lost their sight. Pixium Vision is a clinical stage company in its pivotal trial in Europe. The Prima System is intended to partially replace the normal physiological function of the eye’s photoreceptor cells by electrically stimulating the nerve cells of the inner retina, which then transmit the visual information to the brain via the optic nerve.
The mission of Pneumeric, Inc. is to save lives from traumatic injuries by providing a unique solution to a leading cause of death in young people. The Pneumeric, Inc. Capnotspot© is a medical device designed to detect air expelled from a collapsed lung. The technology was developed at Mayo Clinic and is intended to be the new standard of care for those affected by pneumothorax in a prehospital setting.
Rapid Response Revival (RRR) has developed and is about to deliver to customers, the world’s first affordable, personalized, and cellular IoT connected Automated External Defibrillator (AED) that will transform the global approach to saving lives from sudden cardiac arrest (SCA) in homes. Between 7-9 million people die from sudden cardiac arrest (SCA) each year; about 80 per cent of these deaths occur in homes. SCA kills quickly. Too many people die at home because they don’t receive defibrillation in time. Before now, AEDs (automated external defibrillators) were too expensive for households to own, and for businesses and communities to make defibrillation available everywhere it’s needed. In an emergency where time is everything, Rapid Response revival’s (RRR) patent-protected technology, high-tech medical engineering and design innovation has broken the barriers to accessing the life-saving tools needed to act in time. CellAED® has been certified for sale in over 70 countries. RRR will begin supplying customers in Australia from August 2022 and will continue the rollout of CellAED® to customers in New Zealand and the United Kingdom throughout the first half of 2023.
Revibe Technologies is developing a Wearable (Smart Watch) Digital Therapeutic to treat and assist in monitoring individuals with ADHD. The technology was founded on the data collected from over 15,000 people with ADHD, focus and attention issues which forms the basis of its AI driven personalized therapy.
Rhino HealthTech Inc (Rhino Health) offers an industrial-grade end-to-end analytics platform that enables data collaborations across institutions without ever moving data outside institutional firewalls. The Rhino Health Platform (RHP) accomplishes this by sending algorithms to the data and sharing back only aggregate results (e.g. model weights, summary statistics), instead of pooling data for analysis at a central location. By leaving data at rest and under institutional control at all times, RHP reduces barriers to data collaborations such as Real-World Evidence generation and algorithm development, thus promoting data diversity and cross-functional engagement, which in turn leads to an accelerated pace of innovation.
Impacted earwax is the leading cause of conductive hearing loss according to Harvard Medical School. Syringes, spray bottles, and water flossers are time-consuming, messy, and antiquated. OtoSet® by SafKan Health is the first automated and FDA-cleared ear cleaning device for clinical use. At the push of a button, liquid flow and micro-suction technology combine to automatically break down and remove impacted earwax for a quick, safe, effective, and mess-free earwax removal procedure.
Soundable Health is an early-commercial stage digital health company with proprietary acoustic AI engines and digital audible biomarkers in urinary, respiratory and neuro-muscular diseases. We aim to provide patients and doctors with clinical-grade data that can be used to track various chronic symptoms by analyzing ambient sounds. Raised $5.7 million equity funding and awarded $2 million non-dilutive grant to date, we are looking for a $10 million Series A round fund to commercialize at scale.
Founded by a practicing internal medicine physician, Stethoscover™ was created as an infection control tool for the stethoscope to help ensure patient protection in the care setting since stethoscopes serve as great vectors of pathogen transmission. To help reduce cross-contamination from the stethoscope, our team developed an automated device that dispenses a hygienic stethoscover barrier to ensure touch-free application by the clinician, making patient protection quick and easy. Our unique product offering is practical to deploy and ensures an efficient clinical workflow.
Tada Group AB is a spin-off company from the Clinical Innovation Fellowships, an EIT Health Flagship Initiative. Our strength lies in need-based innovation where we follow the Biodesign methodology to find needs and solve them.
Predictive AI powered by advanced neural networking. Our first product, Preterm AI can identify risk to mothers and babies as early as 8 weeks.
There are over 5 million vascular surgeries every year that use veins as replacement arteries, such as arteriovenous fistulas for chronic kidney disease patients. Because veins are not built like arteries, half of these surgeries fail, drastically increasing mortality and impairing quality of life. VenoStent's Breakthrough Technology, the SelfWrap Bioabsorbable Perivascular Wrap, is in prime position to become the standard of care in vascular surgery and address a >$20B bottoms-up addressable market.
Verdure Imaging replaces the danger, latency, and overhead of CT Scans, MRIs and X-Rays with the safety, speed, and convenience of Ultrasounds. Through its groundbreaking combination of AI and Ultrasound technologies, Verdure is not just displacing current uses of established medical imaging devices, but also has the potential to lead to new standards of care.
VESTECK, Inc. is an early-stage medical device company focused on bringing their proprietary technology to the aortic repair, structural heart and GI markets. Their first product, the "Suture-Tight" nitinol suture delivery catheter will bring a novel technology to endovascular aortic repair market solving a significant global challenge for physicians and patients.
ZKR has developed a new medical device and procedure that addresses chronic knee pain caused by the medical condition Condromalacia Patellae, a degeneration of the shock absorption at the knee cap. Millions of people suffer from this condition, which is caused by inflammation of the underside of the patella and softening of the cartilage. Most sufferers postpone medical intervention and suffer with the pain for years as the condition worsens, because until now, the solution has been major surgery. Now, physicians can offer a truly effective solution, delivering mobility, relief from pain and possibly even avoiding the need for a major knee replacement procedure. Developed by Dr. Jeffrey Halbrecht, a pioneer in minimally invasive techniques in arthroscopic surgery. The company has multiple patents, and has developed prototypes. ZKR is raising capital for product trials.